Haemonetics (NYSE:HAE) Price Target Raised to $74.00

Haemonetics (NYSE:HAE) had its price objective increased by JPMorgan Chase & Co. from $62.00 to $74.00 in a research note issued to investors on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the medical instruments supplier’s stock.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC increased their target price on Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a report on Friday, November 7th. Raymond James Financial reiterated an “outperform” rating and set a $90.00 price target on shares of Haemonetics in a research report on Friday, November 14th. Barrington Research raised their price objective on Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, November 7th. BTIG Research reaffirmed a “buy” rating and set a $88.00 target price on shares of Haemonetics in a report on Friday, November 21st. Finally, Citigroup reduced their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and an average target price of $80.90.

Haemonetics Price Performance

Shares of NYSE HAE opened at $83.46 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The firm has a fifty day moving average of $65.38 and a 200 day moving average of $64.40. The firm has a market cap of $3.91 billion, a PE ratio of 24.40, a PEG ratio of 1.58 and a beta of 0.29. Haemonetics has a one year low of $47.31 and a one year high of $87.32.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. During the same quarter last year, the business earned $1.12 earnings per share. The company’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, research analysts predict that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Trading of Haemonetics

Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its holdings in shares of Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after purchasing an additional 1,678,630 shares in the last quarter. Millennium Management LLC boosted its position in Haemonetics by 4,296.3% in the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after buying an additional 755,592 shares during the period. Norges Bank acquired a new position in shares of Haemonetics in the second quarter worth $36,822,000. Invenomic Capital Management LP increased its position in shares of Haemonetics by 1,691.5% during the third quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after acquiring an additional 470,502 shares during the period. Finally, SG Capital Management LLC increased its position in shares of Haemonetics by 92.5% during the second quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after acquiring an additional 435,660 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.